Wall Street brokerages expect Editas Medicine Inc (NASDAQ:EDIT) to announce sales of $16.30 million for the current quarter, Zacks reports. Four analysts have issued estimates for Editas Medicine’s earnings. The highest sales estimate is $32.00 million and the lowest is $1.50 million. Editas Medicine posted sales of $3.67 million in the same quarter last year, which suggests a positive year over year growth rate of 344.1%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 5th.

According to Zacks, analysts expect that Editas Medicine will report full year sales of $41.49 million for the current fiscal year, with estimates ranging from $27.30 million to $57.82 million. For the next financial year, analysts anticipate that the business will post sales of $33.09 million, with estimates ranging from $20.00 million to $58.10 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Editas Medicine.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. ValuEngine lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday, January 22nd. Finally, Chardan Capital reissued a “buy” rating and issued a $55.00 price target on shares of Editas Medicine in a report on Tuesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $42.50.

In related news, CFO Andrew A. F. Hack sold 6,895 shares of the business’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $21.39, for a total value of $147,484.05. Following the sale, the chief financial officer now directly owns 6,895 shares of the company’s stock, valued at approximately $147,484.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Katrine Bosley sold 12,000 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $31.92, for a total transaction of $383,040.00. Following the completion of the sale, the chief executive officer now directly owns 1,217,066 shares in the company, valued at $38,848,746.72. The disclosure for this sale can be found here. Insiders sold a total of 61,179 shares of company stock worth $1,623,659 over the last ninety days. 5.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. We Are One Seven LLC bought a new stake in Editas Medicine during the 4th quarter worth about $40,000. Ancora Advisors LLC bought a new stake in Editas Medicine during the 3rd quarter worth about $127,000. TRUE Private Wealth Advisors bought a new stake in Editas Medicine during the 3rd quarter worth about $137,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Editas Medicine by 34.2% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,160 shares of the company’s stock worth $113,000 after buying an additional 1,314 shares in the last quarter. Finally, HBK Sorce Advisory LLC bought a new stake in Editas Medicine during the 3rd quarter worth about $203,000. 69.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of EDIT stock traded up $0.22 on Wednesday, hitting $19.97. The stock had a trading volume of 531,083 shares, compared to its average volume of 1,148,200. Editas Medicine has a twelve month low of $17.80 and a twelve month high of $45.02. The firm has a market capitalization of $944.25 million, a price-to-earnings ratio of -6.70 and a beta of 2.56. The company has a quick ratio of 13.13, a current ratio of 13.14 and a debt-to-equity ratio of 0.15.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

See Also: What is channel trading?

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.